Supplementary Materials

This PDF file includes:

  • Methods
  • Fig. S1. Expectorated sputum from CF patients is iron limited.
  • Fig. S2. Iron increases bacterial growth rate in CF sputum.
  • Fig. S3. Gallium inhibits P. aeruginosa growth in CF sputum.
  • Fig. S4. Transposon mutations in PA5248 or the pvdA-fpvI intergenic region modestly increases gallium resistance.
  • Fig. S5. Gallium’s activity used in combination with antibiotics.
  • Fig. S6. Gallium does not attenuate P. aeruginosa killing by human macrophages.
  • Fig. S7. Intravenous gallium produces minimal changes in red blood cell parameters.
  • Fig. S8. Intravenous gallium produces sustained blood and sputum concentrations.
  • Table S1. Results of transposon mutagenesis screening for gallium resistant mutants.
  • Table S2. Full inclusion and exclusion criteria for clinical trial.
  • Table S3. Enrollment table.
  • Table S4. Safety laboratory assessments in CF patients at baseline, day 6, day 14, and day 28.
  • Table S5. Pharmacokinetics of gallium.
  • Table S6. Lung function and microbiology in CF patients at baseline, day 14, and day 28 by dosing cohort.
  • Table S7. Correlation of change in lung function with sputum gallium pharmacokinetics.
  • References (4752)

[Download PDF]